[1]李建南,解敬慧,杜雪梅,等.18F-FDG PET/CT对偶发垂体大腺瘤的诊断价值[J].国际放射医学核医学杂志,2013,37(3):172-176.[doi:10.3760/cma.j.issn.1673-4114.2013.03.011]
　LI Jian-nan,XIE Jing-hui,DU Xue-mei,et al.The value of 18F-FDG PET/CT in the diagnosis of incidental pituitary macroadenoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):172-176.[doi:10.3760/cma.j.issn.1673-4114.2013.03.011]
点击复制

18F-FDG PET/CT对偶发垂体大腺瘤的诊断价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
37
期数:
2013年第3期
页码:
172-176
栏目:
论著
出版日期:
2013-05-25

文章信息/Info

Title:
The value of 18F-FDG PET/CT in the diagnosis of incidental pituitary macroadenoma
作者:
李建南1;  解敬慧1;  杜雪梅1;  陆陟1;  刘静红2;  林尚坤1;  张延军1
1. 116011 大连, 大连医科大学附属第一医院核医学科;
2. 116011 大连, 大连医科大学附属第一医院放射科
Author(s):
LI Jian-nan1;  XIE Jing-hui1;  DU Xue-mei1;  LU Zhi1;  LIU Jing-hong2;  LIN Shang-kun1;  ZHANG Yan-jun1
Department of Nuclear Medicine, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
关键词:
垂体肿瘤; 正电子发射断层显像术; 体层摄影术; X线计算机; 氟脱氧葡萄糖F18
Keywords:
Pituitary neoplasms; Positron emission tomography; Tomography; X ray computer; Fluorodeoxyglucose F18
DOI:
10.3760/cma.j.issn.1673-4114.2013.03.011
摘要:
目的 研究偶发垂体大腺瘤在健康人群及肿瘤患者间发病率的差异,并探讨18F-FDGPET/CT全身显像在偶发垂体大腺瘤诊断中的临床意义。方法 对行PET/CT头部及体部检查的无垂体瘤相关病史的1830例患者进行回顾性分析,其中健康体检者600例,确诊及疑诊肿瘤患者1230例;选择PET显示垂体部位高摄取及同机CT显示垂体占位(病灶短径大于1.0 cm)患者,记录病灶最大标准化摄取值(SUVmax);对入选患者进行随访3~26个月,经病理及MRI明确最终诊断;所有结果采用SPSS16.0软件进行统计学分析,应用Fisher确切检验比较偶发垂体大腺瘤在两组人群间发病率的差异,并评价PET/CT对偶发垂体大腺瘤的诊断价值。结果 15例患者符合上述标准入选,SUVmax为4.2~22.2;1例患者经手术确诊为垂体区转移瘤,SUVmax为19.5;14例患者为偶发垂体大腺瘤,发病率为0.77%,其中源于健康体检者1例,发病率为0.17%,其余13例患者均具有恶性肿瘤病史,发病率为1.06%;PET/CT对偶发垂体大腺瘤的检出率为100%,准确率为93.33%。结论 恶性肿瘤患者组垂体大腺瘤的发病率高于健康体检组;18F-FDG PET/CT显像对偶发垂体大腺瘤具有较高的诊断价值。
Abstract:
Objective To study the incidence difference between healthy people and patients with malignant tumor,and to discuss the diagnostic value of whole-body 18F-FDG PET/CT examination on incidental pituitary macroadenomas.Methods A review analysis was made about the image data of 1830 consecutive subjects with no history of pituitary tumor,including 600 healthy subjects and 1230 patients with known or suspected malignancy who underwent 18F-FDG PET/CT examination.The uptake intensity was recorded by maximum standardized uptake value (SUVmax) of those unexpected pituitary tumor (shot diameter greater than 1.0 cm) with high uptake.The final diagnosis was based on pathology and a 3-26 months follow-up.Compared the incidence difference between healthy people and patients with malignant tumor by Fisher exact test (SPSS 16.0).Assessed the diagnostic efficacy of PET/CT examination.Results Pituitary tumor was accidentally discovered in 15 patients (SUVmax varied between 4.2 and 22.2),including 1 metastases SUVmax 19.5 and 14 (0.77%) pituitary macroadenomas; the incidence rate 0.17% (only 1 case was confirmed of pituitary macroadenomas) among the healthy subjects is higher than that of 1.06% (13 cases) among the malignant tumor patients.The sensitivity and accuracy of PET/CT in detecting large pituitary adenomas were 100% and 93.33% respectively.Conclusions The incidence of pituitary macroadenoma is higher in patients with raligant tumor than that in the healthy controls.PET/CT is of practical significance in the diagnosis of the pituitary macroadenomas.

参考文献/References:

[1] Freda PU,Beckers AM,Katznelson L,et al. Pituitary incidentaloma:an endocrine society clinical practice guideline. J Clin Endocrinol Metab,2011,96(4):894-904.
[2] Hall WA,Luciano MG,Doppman JL,et al. Pituitary magnetic resonance imaging in normal human volunteers:occult adenomas in the general population. ANN Intern Med,1994,120(10):817-820.
[3] Teramoto A,Hirakawa K,Sanno N,et al. Incidental pituitary lesions in 1,000 unselected autopsy specimens. Radiology,1994,193(1):161-164.
[4] Uei Y,Kanzaki M,Yabana T. Incidental adenomas of the human pituitary gland. Endocrine pathology,1994,5(2):90-99.
[5] Buurman H,Saeger W. Subclinical adenomas in postmortem pituitaries:classification and correlations to clinical data Eur J Endocrinol,2006,154(5):753-758.
[6] De Souza B,Brunetti A,Fulham MJ,et al. Pituitary microadenomas:a PET study. Radiology,1990,177(1):39-44.
[7] Jeong SY,Lee SW,Lee HJ,et al. Incidental pituitary uptake on whole-body 18F-FDG PET/CT:a multicentre study. Eur J Nucl Med Mol Imaging,2010,37(12):2334-2343.
[8] Reincke M,Allolio B,Saeger W,et al. The "incidentaloma" of the pituitary gland. Is neurosurgery required?. JAMA,1990,263(20):2772-2776.
[9] Yue NC,Longstreth WT,Elster AD,et al. Clinically serious abnormalities found incidentally at MR imaging of the brain:data from the cardiovascular health study. Radiology,1997,202(1):41-46.
[10] Nammour G M,Ybarra J,Naheedy MH,et al. Incidental pituitary macroadenoma:a population-based study. Am J Med Sci,1997,314(5):287-291.
[11] Hyun SH,Choi JY,Lee KH,et al. Incidental focal 18F-FDG uptake in the pituitary gland:clinical significance and differential diagnostic criteria. J Nucl Med,2011,52(4):547-550.
[12] Hemminki K,Försti A,Ji J. Incidence and familial risks in pituitary adenoma and associated tumors. Endocr Relat Cancer,2007,14(1):103-109.
[13] Vierimaa O,Georgitsi M,Lehtonen R,et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science,2006,312(5777):1228-1230.
[14] Feldkamp J,Santen R,Harms E,et al. Incidentally discovered pituitary lesions:high frequency of macroadenomas and hormone-secreting adenomas-results of a prospective study. Clin Endocrinol,1999,51(1):109-113.
[15] Francavilla TL,Miletich RS,Demichele D,et al. Positron emission tomography of pituitary macroadnomas:hormone production and effects of the rapies. Neurosurgery,1991,28(6):826-833.
[16] Muhr C,Bergstrom M. Positron emission tomography applied in the study of pituitary adenomas. J Endocrinol Invest,1991,14(6):509-528.
[17] Visot A. Neurosurgery and pituitary tumors:etio-pathogenic considerations. Presse Med,2001,30(8):392-394.
[18] Visot A. Neurosurgery and pituitary tumors:surgical indenications and outcome. Presse Med,2001,30(8):401-404.
[19] Mavariakis AN,Tritos NA. Diagnostic and therapeutic approach to pituitary incidentalomas. Endocr Pract,2004,10(5):438-444.

相似文献/References:

[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
　He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
　Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
　Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
　Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
　Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
　Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[8]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
　You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[9]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
　Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
[10]李菲,黄俊星,张俊.18F-FDG PET/CT在食管癌中的临床应用[J].国际放射医学核医学杂志,2016,40(4):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]
　Li Fei,Huang Junxing,Zhang Jun.The clinical application of 18F-FDG PET/CT in esophageal cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):282.[doi:10.3760/cma.j.issn.1673-4114.2016.04.009]

备注/Memo

备注/Memo:
收稿日期:2012-09-19。
通讯作者:张延军,Email:yjzhang78@yahoo.com.cn
更新日期/Last Update: 1900-01-01